About: Medarex

Facets (new session)
Description
Metadata
Settings
- Rule:
- Inverse Functional Properties:
- "Same As":

About: Medarex Goto Sponge NotDistinct Permalink

An Entity of Type : yago:SocialGroup107950920, within Data Space : dbpedia.org associated with source document(s)
QRcode icon

http://dbpedia.org/describe/?url=http%3A%2F%2Fdbpedia.org%2Fresource%2FMedarex

Medarex (former NASDAQ symbol: MEDX ) was an American biopharmaceutical company based in Princeton, New Jersey, with manufacturing facilities in Bloomsbury and Annandale, New Jersey, and research facilities in Milpitas and Sunnyvale, California. In 2009, Medarex was purchased by Bristol Myers Squibb. Medarex developed some of the first transgenic mice with humanized immune systems, in order to generate fully human antibodies. Many of the on-market monoclonal antibodies have been derived from this platform.

Attributes	Values
rdf:type	Thing company schema:Organization dul:Agent dul:SocialPerson agent wikidata:Q24229398 Organization Business enterprise yago:WikicatBiotechnologyCompanies yago:WikicatCompaniesBasedInPrinceton,NewJersey yago:Abstraction100002137 yago:Company108058098 yago:Group100031264 yago:Institution108053576 yago:Organization108008335 yago:YagoLegalActor yago:YagoLegalActorGeo yago:YagoPermanentlyLocatedEntity organisation yago:SocialGroup107950920
rdfs:label	Medarex (en)
rdfs:comment	Medarex (former NASDAQ symbol: MEDX ) was an American biopharmaceutical company based in Princeton, New Jersey, with manufacturing facilities in Bloomsbury and Annandale, New Jersey, and research facilities in Milpitas and Sunnyvale, California. In 2009, Medarex was purchased by Bristol Myers Squibb. Medarex developed some of the first transgenic mice with humanized immune systems, in order to generate fully human antibodies. Many of the on-market monoclonal antibodies have been derived from this platform. (en)
foaf:name	Medarex (en)
name	Medarex (en)
dcterms:subject	Biotechnology companies of the United States Pharmaceutical companies based in New Jersey Pharmaceutical companies disestablished in 2009 Companies formerly listed on the Nasdaq 2009 mergers and acquisitions Bristol Myers Squibb Companies based in Princeton, New Jersey
Wikipage page ID	10806484 (xsd:integer)
Wikipage revision ID	1095742197 (xsd:integer)
Link from a Wikipage to another Wikipage	California Princeton, New Jersey Non-small-cell lung carcinoma Bloomsbury, New Jersey Johnson & Johnson United States Donald L. Drakeman Biotechnology companies of the United States Genmab Monoclonal antibodies Annandale, New Jersey PD-1 Bristol Myers Squibb Pharmaceutical companies based in New Jersey Pharmaceutical companies disestablished in 2009 Tumor necrosis factor alpha Janssen Biotech Dartmouth College Food and Drug Administration Nivolumab Dartmouth Medical School Companies formerly listed on the Nasdaq Ipilimumab 2009 mergers and acquisitions Bristol Myers Squibb Companies based in Princeton, New Jersey Biopharmaceutical Sunnyvale, California T cells dbr:CTLA-4 Milpitas, California New Jersey Squamous-cell carcinoma Simponi
Link from a Wikipage to an external page	https://www.bms.com/
sameAs	Medarex Medarex Medarex Medarex Medarex
dbp:wikiPageUsesTemplate	dbt:Citation_needed dbt:End_date_and_age dbt:Infobox_company dbt:Reflist dbt:Short_description dbt:Start_date_and_age
fate	Acquired by Bristol Myers Squibb (en)
founder	Dr. Edward D. Ball (en) Dr. Michael W. Fanger (en) Dr. Paul M. Guyre (en)
hq location	Princeton, New Jersey United States
industry	Biopharmaceutical
parent	Bristol Myers Squibb (en)
has abstract	Medarex (former NASDAQ symbol: MEDX ) was an American biopharmaceutical company based in Princeton, New Jersey, with manufacturing facilities in Bloomsbury and Annandale, New Jersey, and research facilities in Milpitas and Sunnyvale, California. In 2009, Medarex was purchased by Bristol Myers Squibb. Medarex developed monoclonal antibodies to CTLA-4 and PD-1, which are proteins on the surface of T cells. T cells attack cancer cells, but CTLA-4 and PD-1 act as "brakes" on the T cell's anti-cancer activities. The monoclonal antibodies bind to these proteins and block them, releasing the T cell to attack cancer cells. Several monoclonal antibodies developed by Medarex have been approved for disease therapy. In 2009, the U.S. Food and Drug Administration approved Simponi, a human monoclonal antibody to tumor necrosis factor alpha co-developed with Johnson & Johnson's Janssen Biotech, for treatment of arthritis. In 2011, the U.S. FDA approved ipilimumab, a monoclonal antibody to CTLA-4, for treatment of metastatic melanoma.In 2014, the U.S. FDA approved nivolumab, a monoclonal antibody to PD-1, for treatment of advanced melanoma. Its use was expanded to the treatment of squamous non-small-cell lung carcinoma in 2015. Medarex developed some of the first transgenic mice with humanized immune systems, in order to generate fully human antibodies. Many of the on-market monoclonal antibodies have been derived from this platform. (en)
gold:hypernym	Company
prov:wasDerivedFrom	wikipedia-en:Medarex?oldid=1095742197&ns=0
page length (characters) of wiki page	6325 (xsd:nonNegativeInteger)
fate	Acquired byBristol Myers Squibb (en)
founding year	1987-01-01 (xsd:gYear)
headquarter	Princeton, New Jersey United States
industry	Biopharmaceutical
parent company	Bristol Myers Squibb
foaf:isPrimaryTopicOf	wikipedia-en:Medarex
is Link from a Wikipage to another Wikipage of	Donald L. Drakeman

Faceted Search & Find service v1.17_git139 as of Feb 29 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 08.03.3330 as of Mar 19 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (378 GB total memory, 56 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software